In January 2025, the US FDA published a draft regulatory guidance entitled “The Considerations for Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products”.
The regulatory guidance aimed at formulating a risk-based credibility assessment framework to examine the usefulness of AI models in decision-making about the safety and efficacy of drugs and biological products. The 2025 guidelines also emphasize transparency, data quality, and continuous monitoring.
From February 2, 2025, pharmaceutical companies in the European Union (EU) region must comply with AI literacy requirements and avoid AI practices that are prohibited under Article 514. By August 2, 2025, obligations for general-purpose AI models will take effect, which might impact AI-driven drug development and regulatory submissions.8
Corporate Sustainability Reporting Directive (CSRD), an EU directive mandate effective from 2025, requires pharmaceutical companies to disclose environmental, social, and governance (ESG) activities to strengthen transparency in sustainability efforts.
The Digital Operational Resilience Act (DORA) is an EU regulation, effective from January 17, 2025, that focuses on ensuring a secure financial system in Europe.
DORA ensures strong cybersecurity resilience measures for financial entities for higher transparency in financial transactions and supply chain financing in pharmaceutical companies.
The FDA encourages pharmaceutical companies to adopt advanced manufacturing technologies (AMTs) to improve the reliability and robustness of the manufacturing process.
AMTs would be significantly beneficial because they could reduce drug development time and enhance product quality.
Reference:
Regulatory Trends in Pharma Manufacturing: Key Changes to Watch in 2025
Today we announce that Exim is rebranding as ExSyn. We are presenting a new brand identity and website as a reflection of our relentless transformation over the course of 30 years serving the pharma and chemical industries. The new brand builds upon our core strengths as a sourcing company and captures our most essential duty: helping improve people’s health and lives.
Phosphorodiamidites are a unique class of phosphorus-based compounds characterized by one P–O bond and two P–N moieties. 2-Cyanoethyl tetraisopropylphosphorodiamidite plays a crucial role in solid-phase oligonucleotide synthesis. Beyond their application as synthetic precursors for oligonucleotides, phosphorodiamidites have also been reported as valuable starting materials for the synthesis of industrially relevant polymers and flame-resistant materials, including adhesives, coatings, and laminates.
Ferric maltol is an oral iron complex composed of ferric iron (Fe³⁺) chelated with maltol, designed to improve iron absorption while reducing common gastrointestinal side effects associated with traditional iron salts. It is primarily used in the management of iron deficiency with better tolerability.
Meet the ExSyn team at Biologics Festival India 2025
February 10 – 11, 2026
Hyatt Regency, Pune, India